Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zafgen Inc (ZFGN)

Zafgen Inc (ZFGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,265
  • Shares Outstanding, K 37,370
  • Annual Sales, $ 0 K
  • Annual Income, $ -61,370 K
  • 60-Month Beta -0.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.36
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.47
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/06/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.25
  • Number of Estimates 2
  • High Estimate -0.22
  • Low Estimate -0.29
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +39.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.63 +15.81%
on 09/10/19
0.94 -22.38%
on 08/14/19
-0.21 (-22.38%)
since 08/13/19
3-Month
0.63 +15.81%
on 09/10/19
1.46 -50.03%
on 06/19/19
-0.67 (-47.89%)
since 06/13/19
52-Week
0.63 +15.81%
on 09/10/19
12.35 -94.09%
on 09/27/18
-9.95 (-93.17%)
since 09/13/18

Most Recent Stories

More News
Zafgen to Explore Strategic Alternatives

Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic...

ZFGN : 0.73 (+3.78%)
Zafgen Reports Second Quarter 2019 Operating and Financial Results

Agreement reached with U.S. FDA on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins

ZFGN : 0.73 (+3.78%)
Zafgen to Present at the Wedbush PacGrow Healthcare Conference

Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic...

ZFGN : 0.73 (+3.78%)
Zafgen Announces Agreement with U.S. Food and Drug Administration on New Nonclinical Study Design for ZGN-1061

Alignment reached on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins

ZFGN : 0.73 (+3.78%)
Zafgen Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the American Diabetes Association's 79th Scientific Sessions

Delivered comprehensive oral presentation on both cohorts of the clinical trial, including previously announced results for second cohort evaluating doses up to 1.8 mg

ZFGN : 0.73 (+3.78%)
Zafgen Announces Regulatory Update on ZGN-1061

Received FDA Type A meeting minutes related to previously announced clinical hold

ZFGN : 0.73 (+3.78%)
Zafgen Reports First Quarter 2019 Operating and Financial Results

Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061

ZFGN : 0.73 (+3.78%)
Zafgen to Announce First Quarter 2019 Financial Results

Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic...

ZFGN : 0.73 (+3.78%)
Zafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zafgen, Inc. (Nasdaq:ZFGN) (the "Company") a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by...

ZFGN : 0.73 (+3.78%)
Lifshitz & Miller LLP Announces Investigation of Amyris, Inc., iRhythm Technologies, Inc., Orion Group Holdings, Inc., Osmotica Pharmaceuticals plc, Quantenna Communications, Inc., WABCO Holdings, Inc. and Zafgen, Inc.

Amyris, Inc. (AMRS)

QTNA : 24.51 (+1.07%)
AMRS : 4.80 (+1.69%)
WBC : 134.22 (-0.19%)
IRTC : 78.62 (-0.24%)
ORN : 5.14 (unch)
ZFGN : 0.73 (+3.78%)
OSMT : 3.69 (-0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ZFGN with:

Business Summary

Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity...

See More

Key Turning Points

2nd Resistance Point 0.75
1st Resistance Point 0.74
Last Price 0.73
1st Support Level 0.71
2nd Support Level 0.69

See More

52-Week High 12.35
Fibonacci 61.8% 7.88
Fibonacci 50% 6.49
Fibonacci 38.2% 5.11
Last Price 0.73
52-Week Low 0.63

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar